Objective: To analyze the clinical characteristics and prognostic factors of patients with Hodgkin's lymphoma(HL). Methods: The clinical data of HL patients who were newly treated in Guizhou Cancer Hospital from August 2007 to March 2019 was retrospectively collected, and the efficacy and prognostic factors were analyzed. Results: The clinical data of a total of 222 patients were analyzed in this study. The 5-year progression-free survival (PFS) and overall survival (OS)rate of them were 82.8% and 81.3%, respectively. The 5-year PFS rate and OS rate of early (stage Ⅰ-Ⅱ) HL were 87.3% and 86.1%, respectively, and the 5-year PFS rate and OS rate of progressive (stage Ⅲ-Ⅳ) HL were 77.9% and 76.3%, respectively. Among the 118 patients with early Hodgkin's lymphoma, the complete remission(CR) rate of chemotherapy alone was 55.6%(15/27), and chemotherapy plus radiotherapy was 86.8% (79/91), the difference between which was statistically significant (P<0.05). Compared with chemotherapy plus radiotherapy in early stage patients, 5-year PFS (93.0%) and 5-year OS (92.0%) rate in patients with chemotherapy plus radiotherapy were better than those with chemotherapy alone which were 63.7% and 62.1%, respectively. Multivariate analysis showed that age, LDH, ABVD cycle number and chemoradiotherapy were independent prognostic factors for 5-year OS and PFS rate in HL patients. The adverse reactions were increased level Ⅰ-Ⅱ aminotransferase with an incidence of 47.7% (106/222), decreased level Ⅰ-Ⅱ neutrophils with an absolute value of 54.1% (120/222), and decreased level Ⅲ-Ⅳ neutrophils with an absolute value of 45.9% (102/222). No adverse cardiac and pulmonary reactions or secondary tumors associated with chemotherapy was found in all patients. Conclusions: HL is a type of malignant tumor with good prognosis, and the short-term and long-term efficacy of chemotherapy combined with radiotherapy in early patients is better than that of chemotherapy alone. Age, LDH, ABVD cycle number and chemoradiotherapy are associated with prognosis in patients with Hodgkin's lymphoma. Adverse reactions can be tolerated.
目的： 分析初治霍奇金淋巴瘤（HL）患者的临床特征及预后相关因素。 方法： 收集贵州医科大学附属医院2007年8月至2019年3月期间初治HL患者的临床资料，对其临床特征、治疗效果和预后因素进行回顾性分析。 结果： 共有222例患者纳入研究，5年无进展生存（PFS）率、总生存（OS）率分别为82.8%、81.3%；早期（Ⅰ~Ⅱ期）HL的5年PFS率、OS率分别为87.3%、86.1%；进展期（Ⅲ~Ⅳ期）HL的5年PFS率、OS率分别为77.9%、76.3%。118例早期HL中，单纯化疗完全缓解（CR）率55.6%（15/27），化疗联合放疗86.8%（79/91），差异有统计学意义（P<0.05）；早期患者单纯化疗与化疗加放疗比较，化疗+放疗者5年PFS率（93.0%）优于单纯化疗者（63.7%），5年OS率（92.0%）优于单纯化疗者（62.1%）。多因素分析显示：年龄、乳酸脱氢酶（LDH）、ABVD周期数及放化联合治疗是影响HL患者5年OS和PFS率的独立预后因素。主要不良反应为Ⅰ~Ⅱ级转氨酶升高47.7%（106/222），Ⅰ~Ⅱ级的中性粒细胞降低54.1%（120/222），Ⅲ~Ⅳ级中性粒细胞绝对值降低45.9%（102/222），所有患者中未出现与化疗相关的心脏及肺的不良反应及第二肿瘤。 结论： HL是一种预后较好的恶性肿瘤，早期患者化疗联合放疗的近期及远期疗效均优于单纯化疗者。年龄、LDH水平、ABVD周期数及放化联合治疗与HL患者的预后相关；不良反应可耐受。.
Keywords: Lymphoma; Prognosis; Treatment outcome.